NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

FibroGen Inc (MX: FGEN)

 
FGEN Technical Analysis
4
As on 3rd Dec 2025 FGEN STOCK Price closed @ 149.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 23.19 & Strong Buy for SHORT-TERM with Stoploss of 9.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

FGENSTOCK Price

Open 149.00 Change Price %
High 149.00 1 Day -18.00 -10.78
Low 149.00 1 Week -50.00 -25.13
Close 149.00 1 Month 142.80 2303.23
Volume 15 1 Year 141.10 1786.08
52 Week High 223.00 | 52 Week Low 5.08
 
MX Mexico Most Active Stocks
AMXL 19.28 -0.36%
PV 8.50 7.32%
ALFAA 15.28 0.92%
WALMEX 58.87 -1.59%
FR 613.10 0.02%
CEMEXCPO 19.98 0.71%
LABB 18.69 1.63%
GFNORTEO 174.81 -0.69%
FUNO11 26.73 1.67%
NEMAKA 4.08 0.74%
 
MX Mexico Top Gainers Stocks
ALEATIC 49.86 141.69%
MKSN 54.86 92.49%
GNW 160.21 57.38%
GNW 160.21 57.38%
KPNN 84.19 36.76%
LYGN 94.00 14.63%
UTSI 50.85 13.00%
UTSI 50.85 13.00%
CC 222.00 11.00%
CC 222.00 11.00%
 
MX Mexico Top Losers Stocks
AGLN 502.53 -25.55%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
IP 872.75 -23.50%
GOLN 54.50 -17.05%
JKSN 613.50 -14.32%
DAIN 1399.55 -13.16%
FGEN 149.00 -10.78%
 
 
FGEN
Daily Charts
FGEN
Intraday Charts
Whats New @
Bazaartrend
FGEN
Free Analysis
 
FGEN Important Levels Intraday
RESISTANCE149.00
RESISTANCE149.00
RESISTANCE149.00
RESISTANCE149.00
RESISTANCE149.00
RESISTANCE149.00
RESISTANCE149.00
RESISTANCE149.00
 
FGEN Forecast December 2025
4th UP Forecast162.22
3rd UP Forecast157.98
2nd UP Forecast155.36
1st UP Forecast152.74
1st DOWN Forecast145.26
2nd DOWN Forecast142.64
3rd DOWN Forecast140.02
4th DOWN Forecast135.78
 
FGEN Weekly Forecast
4th UP Forecast155.15
3rd UP Forecast153.18
2nd UP Forecast151.96
1st UP Forecast150.74
1st DOWN Forecast147.26
2nd DOWN Forecast146.04
3rd DOWN Forecast144.82
4th DOWN Forecast142.85
 
FGEN Forecast2025
4th UP Forecast572.94
3rd UP Forecast436.98
2nd UP Forecast352.94
1st UP Forecast268.9
1st DOWN Forecast29.1
2nd DOWN Forecast-54.94
3rd DOWN Forecast-138.98
4th DOWN Forecast-274.94
 
 
FGEN Other Details
Segment EQ
Market Capital 21147756544.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
FGEN Address
FGEN
 
FGEN Latest News
 
Your Comments and Response on FibroGen Inc
 
FGEN Business Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 409 Illinois Street, San Francisco, CA, United States, 94158
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service